Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: A randomised controlled trial

The Lancet Respiratory Medicine

Volumn 1, Issue 1, 2013, Pages 32-42

  Patel, Mitesh ^a,b,c   Pilcher, Janine ^a,b   Pritchard, Alison ^a   Perrin, Kyle ^a,b   Travers, Justin ^a   Shaw, Dominick ^c   Holt, Shaun ^a,d,e   Harwood, Matire ^a   Black, Peter ^f   Weatherall, Mark ^b,g   Beasley, Richard ^a,b,e,g  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d Victoria University of Wellington ^*

^e VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE; HYDROCORTISONE; PREDNISONE; SALBUTAMOL; ANTIASTHMATIC AGENT; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FORMOTEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; DRUG THERAPY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; NEW ZEALAND; PATIENT MONITOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SINGLE MAINTENANCE AND RELIEVER THERAPY; TREATMENT OUTCOME; COMPLICATION; DRUG COMBINATION; HOSPITALIZATION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, INHALATION; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BUDESONIDE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 84877093623     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70007-9     Document Type: Article

References (40)

1. Global Initiative for Asthma (GINA) 2011 Global Strategy for Asthma Management and Prevention, (accessed Oct 17, 2012). http://www.ginasthma.org.
2. British guideline on the management of asthma. A national clinical guideline British Thoracic Society, Scottish Intercollegiate Guidelines Network, (accessed Oct 17, 2012). http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/sign101%20Jan%202012.pdf.
3. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005, 171:129-136.
4. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006, 368:744-753.
5. Abramson MJ, Bailey MJ, Couper FJ, et al. Are asthma medications and management related to deaths from asthma?. Am J Respir Crit Care Med 2001, 163:12-18.
6. Spitzer W, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992, 326:501-506.
7. Suissa S, Blais L, Ernst P Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 1994, 7:1602-1609.
8. Eisner MD, Lieu TA, Chai F, et al. Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. Eur Respir J 2001, 17:233-240.
9. Burgess SW, Wilson SS, Cooper DM, Sly PD, Devadason SG In vitro evaluation of an asthma dosing device: the smart-inhaler. Respir Med 2006, 100:841-845.
10. Patel M, Pilcher J, Chan A, Perrin K, Black P, Beasley R Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: implications for asthma clinical trial use. J Allergy Clin Immunol 2012, 130:1420-1422.
11. Patel M, Pilcher J, Travers J, et al. Use of metered-dose inhaler electronic monitoring in a real-world asthma randomized controlled trial. J Allergy Clin Immunol: In Practice 2013, 1:83-91.
12. Rand CS, Wise RA, Nides M, et al. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992, 146:1559-1564.
13. National Asthma Council Australia Symbicort SMART Asthma Action Plan, (accessed Oct 17, 2012). http://www.nationalasthma.org.au/health-professionals/tools-for-primary-care/asthma-action-plans/asthma-action-plan-library.
14. Holt S, Masoli M, Beasley R The use of the self-management plan system of care in adult asthma. Prim Care Respir J 2004, 13:19-27.
15. Balanag VM, Yunus F, Yang PC, Jorup C Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther 2006, 19:139-147.
16. Rubinfeld AR, Scicchitano R, Hunt A, Thompson PJ, Van Nooten A, Selroos O Formoterol Turbuhaler as reliever medication in patients with acute asthma. Eur Respir J 2006, 27:735-741.
17. Aaronson D, Kaiser H, Dockhorn R, et al. Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: a dose-response study. J Allergy Clin Immunol 1998, 101:312-319.
18. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009, 180:59-99.
19. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999, 14:902-907.
20. Windom HH, Burgess CD, Crane J, Pearce N, Kwong T, Beasley R The self-administration of inhaled beta agonist drugs during severe asthma. N Z Med J 1990, 103:205-207.
21. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005, 60:302-308.
22. Pauwels RA, Sears MR, Campbell M, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003, 22:787-794.
23. Fraser PM, Speizer FE, Waters SD, Doll R, Mann NM The circumstances preceding death from asthma in young people in 1968 to 1969. Br J Dis Chest 1971, 65:71-84.
24. Cates CJ, Lasserson TJ Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children. Cochrane Database Syst Rev 2009, 1. CD007085.
25. Barnes PJ Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007, 29:587-595.
26. Sovani MP, Whale CI, Oborne J, et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. Br J Gen Pract 2008, 58:37-43.
27. Rodrigo GJ Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest 2006, 130:1301-1311.
28. O'Connor RD, Bleecker ER, Long A, et al. Subacute lack of asthma control and acute asthma exacerbation history as predictors of subsequent acute asthma exacerbations: evidence from managed care data. J Asthma 2010, 47:422-428.
29. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med 2002, 165:1353-1358.
30. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989, 1:917-922.
31. Stolley PD, Schinnar R Association between asthma mortality and isoproterenol aerosols: a review. Prev Med 1978, 7:519-538.
32. Crane J, Pearce N, Burgess C, Woodman K, Robson B, Beasley R Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int J Epidemiol 1992, 21:737-744.
33. Sears MR, Radner F Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med 2009, 103:1960-1968.
34. Rothwell PM External validity of randomised controlled trials: " To whom do the results of this trial apply?" Lancet 2005, 365:82-93.
35. Morice AH, Hochmuth L, Ekelund J, Thoren A, Puterman AS Comparable long-term safety and efficacy of a novel budesonide/formoterol pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma. Pulm Pharmacol Ther 2008, 21:32-39.
36. Morice AH, Peterson S, Beckman O, Osmanliev D Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. Int J Clin Pract 2007, 61:1874-1883.
37. Perrin K, Williams M, Wijesinghe M, James K, Weatherall M, Beasley R Randomized controlled trial of adherence with single or combination inhaled corticosteroid/long-acting beta-agonist inhaler therapy in asthma. J Allergy Clin Immunol 2010, 126:505-510.
38. Hampel FC, Martin P, Mezzanotte WS Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids. J Asthma 2008, 45:265-272.
39. Rosenborg J, Larsson R, Rott Z, Bocskei C, Poczi M, Juhasz G Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Respir Med 2002, 96:412-417.
40. Barnes PJ, Pedersen S, Busse WW Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998, 157:S1-53.